0001564590-20-054498.txt : 20201118 0001564590-20-054498.hdr.sgml : 20201118 20201118170502 ACCESSION NUMBER: 0001564590-20-054498 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20201113 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONSTELLATION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001434418 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38584 FILM NUMBER: 201325856 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-714-0555 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 cnst-8k_20201113.htm 8-K cnst-8k_20201113.htm
false 0001434418 0001434418 2020-11-13 2020-11-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2020

 

 

Constellation Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

 

 

 

 

 

Delaware

 

001-38584

 

26-1741721

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

215 First Street, Suite 200

Cambridge, Massachusetts

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (617714-0555

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CNST

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 



Item 1.01Entry into a Material Definitive Agreement.

On November 13, 2020, Constellation Pharmaceuticals, Inc. (the “Company”) entered into a lease (the “New Lease”) with ARE-MA Region No. 75, LLC, a Delaware limited liability company (the “Landlord”), effective as of November 13, 2020, pursuant to which the Company will lease approximately 79,155 square feet of office and laboratory space located at 100 Talcott Street in Watertown, Massachusetts (the “New Premises”).

The date on which the Company will become responsible for paying rent under the New Lease will be December 24, 2021 (the “Commencement Date”). The New Lease will have a ten-year term. The New Lease also provides the Company with an option to extend the New Lease for an additional five-year term. The Company’s monthly base rent for the New Premises will be $467,978.66, and will increase on each anniversary of the Commencement Date by approximately 3% per annum, up to a maximum monthly base rent of $610,606.01 during the ten-year term. The Company’s expected contractual obligation for base rent over this term is approximately $64.4 million.

The Company will post a customary letter of credit in the amount of approximately $2.8 million as a security deposit pursuant to the New Lease. The Company expects the New Premises to be ready for occupancy in late 2021 and intends to relocate its corporate headquarters to the New Premises at such time.

On November 13, 2020, the Company entered into a Sixth Amendment to Lease (the “Lease Amendment”) with ARE-MA Region No. 38, LLC (the “Existing Landlord”), amending the Lease Agreement, dated as of February 5, 2010, by and between the Company and the Existing Landlord, as amended (the “Existing Lease”). The Lease Amendment provides that the Existing Lease will terminate sixty calendar days from the Commencement Date for the New Lease.

The foregoing summaries of the principal terms of the New Lease and the Lease Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of the New Lease and the Lease Amendment, copies of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSTELLATION PHARMACEUTICALS, INC.

 

 

 

 

Date: November 18, 2020

 

 

 

By:

 

/s/ Emma Reeve

 

 

 

 

 

 

Name: Emma Reeve

 

 

 

 

 

 

Title: Chief Financial Officer

 

EX-101.SCH 2 cnst-20201113.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 cnst-20201113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 4 cnst-20201113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 cnst-8k_20201113_htm.xml IDEA: XBRL DOCUMENT 0001434418 2020-11-13 2020-11-13 false 0001434418 8-K 2020-11-13 Constellation Pharmaceuticals, Inc. DE 001-38584 26-1741721 215 First Street Suite 200 Cambridge MA 02142 617 714-0555 false false false false Common Stock, $0.0001 par value per share CNST NASDAQ true false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 13, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2020
Entity Registrant Name Constellation Pharmaceuticals, Inc.
Entity Central Index Key 0001434418
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-38584
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-1741721
Entity Address, Address Line One 215 First Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 714-0555
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CNST
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cnst-8k_20201113.htm cnst-20201113.xsd cnst-20201113_lab.xml cnst-20201113_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cnst-8k_20201113.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cnst-8k_20201113.htm" ] }, "labelLink": { "local": [ "cnst-20201113_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cnst-20201113_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cnst-20201113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cnst", "nsuri": "http://www.constellationpharma.com/20201113", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "cnst-8k_20201113.htm", "contextRef": "C_0001434418_20201113_20201113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "cnst-8k_20201113.htm", "contextRef": "C_0001434418_20201113_20201113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.constellationpharma.com/20201113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001564590-20-054498-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-054498-xbrl.zip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